A Study Evaluating the Safety and Efficacy of the BioFreedom Biolimus A9 Coated Cobalt Chromium Coronary Stent System in Patients at High Risk of Bleeding

Trial Profile

A Study Evaluating the Safety and Efficacy of the BioFreedom Biolimus A9 Coated Cobalt Chromium Coronary Stent System in Patients at High Risk of Bleeding

Recruiting
Phase of Trial: Phase II

Latest Information Update: 27 Nov 2017

At a glance

  • Drugs Umirolimus (Primary)
  • Indications Coronary artery disease
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Biosensors Europe
  • Most Recent Events

    • 21 Nov 2017 Status changed from not yet recruiting to recruiting.
    • 24 Aug 2017 Planned End Date changed from 30 Nov 2020 to 30 Dec 2020.
    • 24 Aug 2017 Planned primary completion date changed from 31 Oct 2019 to 30 Nov 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top